Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2012

View Archived Issues

Promising data presented from phase II Cinryze combination trial

GeoVax obtains FDA approval to advance adjuvanted HIV vaccine to clinic

Studies address suitability of allopregnanolone to treat Niemann-Pick disease type C

GM-CSF-adjuvanted vaccine provides long-term protection in HIV model

Hadasit Bio-Holdings to receive further funding from Israeli government

FDA approves first cell-based product made from allogeneic human cells and bovine collagen

Immunogenicity and favorable tolerability reported for H5N1 flu vaccine

New data reported on biOasis immunoconjugate for HER2+ breast cancer

Epistem and GlaxoSmithKline enter biomarker collaboration

Enrollment begins in phase I RX-3117 trial

Calcium channel blocker for hypertension clear to enter clinical testing in China

PX'Therapeutics begins phase I trial of HIV vaccine

Calzada subsidiary discloses encouraging in vitro data on AOD-9603

Hybrigenics clear to conduct phase II inecalcitol study in CLL

Hutchison MediPharma reports new JAK inhibitors

Merck KGaA announces new inhibitors of FADK 1

Isotechnika and FDA reach SPA agreement on voclosporin trial

Novel caspase inhibitors discovered at Banyan Biomarkers

Phase I study of CBLB-502 advances

Novel apoptosis inducers prepared by U.S. university scientists

New Trevena G protein-biased mu opioid receptor ligand has analgesic activity

New RSV vaccines developed at GenVec

Phase III OMS-302 study meets endpoints

FDA accepts CRTX-080 NDA for filing

Attogen patents novel FGFR2IIIc-specific antibodies

Abbott identifies new potential analgesics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...